drugset / Trial / NCT06035393

A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT06035393

Phase 2 Terminated 82 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a randomized, double blind, double dummy, active-controlled, parallel-group study to assess the efficacy and Safety of HRG2005 inhalation in patients with moderate to severe chronic obstructive pulmonary disease. Approximately 200 patients with moderate to severe COPD will be randomized into the study.

Timeline

Start
2024-01-15
Primary completion
2025-02-17
Completion
2025-02-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Glycopyrronium Unknown Inhaled
Subject HRG2005 Unknown Inhaled
Subject Indacaterol Other / unclassified Inhaled